Respiratory syncytial virus (RSV) disease and prospects for its control

Antiviral Research

Volumn 39, Issue 2, 1998, Pages 63-79

  Wyde, Philip R ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Antivirals; Chemotherapy; Immunoglobulins; Respiratory disease; Ribavirin; RSV

Indexed keywords

5 ETHYNYL 4 IMIDAZOLECARBOXAMIDE 1 RIBOSIDE; ANTIINFECTIVE AGENT; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; IMMUNOGLOBULIN; NEPLANOCIN A; NUCLEOSIDE ANALOG; PIRAZOFURIN; RESPIRATORY SYNCYTIAL VIRUS VACCINE; RIBAMIDINE; RIBAVIRIN; RIMANTADINE;

ANTIVIRAL ACTIVITY; HUMAN; LUNG INFECTION; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; VIRUS INFECTION;

RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS; SYNCYTIAL VIRUS;

EID: 0032428770     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(98)00029-1     Document Type: Article

References (200)

1. Abman S.H., Ogle J.W., Butler-Simon N., Rumac C.M., Accurso F.J. Role of respiratory syncytial virus in early hospitalizations for respiratory distress in young infants with cystic fibrosis. J. Pediatr. 113:1988;826-830.
2. Agius G., Dindinaud G., Biggar R.J., Peyre R., Vaillant V., Ranger S., Poupet J.Y., Cisse M.F., Castets M. An epidemic of respiratory syncytial virus in elderly people: clinical and serological findings. J. Med. Virol. 30:1990;117-127.
3. Akerlind B., Norrby E., Orvell C., Mufson M.A. Respiratory syncytial virus: heterogeneity of subgroup B strains. J. Gen. Virol. 69:1988;2145-2154.
4. Alper J. Computer-aided design of antiviral agents. ASM News. 56:1990;269-271.
5. Anderson L.J., Hierholzer J.C., Tsou C., Hendry R.M., Fernie B.F., Stone Y., McIntosh K. Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies. J. Infect. Dis. 151:1985;626-633.
6. Anonymous Proceedings of the Eastern Pennsylvania Branch of the American Society for Microbiology Symposium of Innovations in antiviral development and the detection of virus infections. Adv. Exp. Med. Biol. 312:1990;1-209.
7. Balzarini J., Karlsson A., Wang L., Bohman C., Horska K., Votruba I., Fridland A., Van Aerschot A., Herdewijn P., De Clercq E. Eicar (5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamid e), a novel potent inhibitor of inosinate dehydrogenase activity and guanylate biosynthesis. J. Biol. Chem. 268:1993;24591-24598.
8. Barnard D.L., Hill C.L., Gage T., Matheson J.E., Huffman J.H., Sidwell R.W., Otto M.I., Schinazi R.F. Potent inhibition of respiratory syncytial virus by polyoxometalates of several structural classes. Antiviral Res. 34:1997;27-37.
9. Barry W., Cockburn F., Cronall R., Price J.F., Sutherland G., Vardag A. Ribavirin aerosol for acute bronchiolitis. Arch. Dis. Child. 61:1986;593-597.
10. Belshe R.B., Van Voris L.P., Mufson M.A. Parenteral administration of live RSV vaccine: results of a field trial. J. Infect. Dis. 145:1982;311-319.
11. Belshe R.B., Anderson E.L., Walsh E.E. Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children. J. Infect. Dis. 168:1993;1024-1029.
12. Bowden R.A. Respiratory virus infections after marrow transplantation: The Fred Hutchinson Cancer Research Center Experience. Am. J. Med. 102:1997;27-30.
13. Brandt C.D., Kim H.W., Arrobio J.O., Jeffries B.C., Wood S.C., Chanock R.M., Parrott R.H. Epidemiology of respiratory syncytial virus infection in Washington, DC. III. Composite analysis of eleven consecutive yearly epidemics. Am. J. Epidemiol. 98:1973;355-364.
14. Brandt C., Power U.F., Plotnicky Gilquin H., Huss T., Nguyen T., Lambert P.H., Binz H., Siegrist C.A. Protective immunity against respiratory syncytial virus in early life after murine maternal or neonatal vaccination with the recombinant G fusion protein BBG2Na. J. Infect. Dis. 176:1997;884-891.
15. Brideau R.J., Walters R.J., Stier M.A., Wathen M.W. Protection of cotton rats against human respiratory syncytial virus vaccination with a novel chimeric FG glycoprotein. Gen. Virol. 70:1989;2637-2644.
16. Bruhn F.W., Mokrohisky S.T., McIntosh K. Apnea associated with respiratory syncytial virus infection in young infants. J. Pediatr. 90:1977;382-386.
17. Chandwani S., Borkowsky W., Krasinski K., Lawrence R., Welliver R. Respiratory syncytial virus infection in human immunodeficiency virus-infected children. J. Pediatr. 117:1990;251-254.
18. Chanock R.M., Finberg L. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). II. Epidemiological aspects of infection in infants and young children. Am. J. Hyg. 66:1957;291-300.
19. Chanock R.M., Roizman B., Meyers R. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent. I. Isolation, properties and characterization. Am. J. Hyg. 66:1957;281-290.
20. Chen X., Schneller S.W., Ikeda S., Snoeck R., Andrei G., Balzarini J., De Clercq E. Synthesis and antiviral activity of 5′-deoxypyrazofuin. J. Med. Chem. 36:1993;3727-3730.
21. Chiba T., Shigeta S., Numazaki Y. Inhibitory effect of pyridobenzazoles on virus replication in vitro. Biol. Pharm. Bull. 18:1995;1081-1083.
22. Chipps B.E., Sullivan W.F., Portnoy J.M. Alpha-2A-interferon for treatment of bronchiolitis caused by respiratory syncytial virus. Pediatr. Infect. Dis. J. 12:1993;653-658.
23. Cirino N.M., Li G., Xiao W., Torrence P.F., Silverman R.H. Targeting RNA decay with 2′,5′ oligoadenylate-antisense in respiratory syncytial virus-infected cells. Proc. Natl. Acad. Sci. USA. 94:1997;1937-1942.
24. Collins P.L., Purcell R.H., London W.T., Lawrence L.A., Chanock R.M., Murphy B.R. Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus. Vaccine. 8:1990;164-168.
25. Committee on Infectious Diseases Use of ribavirin in the treatment of respiratory syncytial virus in infection. Pediatrics. 92:1993;501-504.
26. Connors M., Giese N.A., Kulkarni A.B., Firestone C.Y., Morse III H.C., Murphy B.R. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J. Virol. 68:1994;5321-5325.
27. Conrad D.A., Christenson J.C., Waner J.L., Marks M.I. Aerosolized ribavirin treatment of respiratory syncytial virus infection in infants hospitalized during an epidemic. Pediatr. Infect. Dis. J. 6:1987;152-158.
28. Crowe J.E. Jr. Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). Vaccine. 13:1995;415-421.
29. Crowe J.E., Bui P.T., Davis A.R., Chanock R.M., Murphy B.R. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine. 12:1994;783-790.
30. Crowe J.E. Jr., Collins P.L., London W.T., Chanock R.M., Murphy B.R. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Vaccine. 11:1993;1395-1404.
31. De Clercq E. S-Adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents. Biochem. Pharmacol. 36:1987;2567-2575.
32. De Clercq E. Antiviral activity spectrum and target of action of different classes of nucleoside analogues. Nucleosides Nucleotides. 13:1994;1271-1295.
33. De Clercq E. Perspectives for the chemotherapy of respiratory syncytial virus (RSV) infections. Int. J. Antimicrob. Agents. 7:1996;193-202.
34. De Clercq E., Cools M., Balzarini J., Snoeck R., Andrei G., Hosoya M., Shigeta S., Ueda T., Minakawa N., Matsuda A. Antiviral activities of 5-ethynyl-1-beta-D- ribofuranosylimidazole-4-carboxamide and related compounds. Antimicrob. Agents Chemother. 35:1991;679-684.
35. De Clercq E., Murase J., Marquez V.E. Broad-spectrum antiviral and cytocidal activity of cyclopentenylcytosine, a carbocyclic nucleoside targeted at CTP synthetase. Biochem. Pharmacol. 41:1991;1821-1829.
36. DeVincenzo J.P., Leombruno D., Soiffer R.J., Siber G.R. Immunotherapy of respiratory syncytial virus pneumonia following bone marrow transplantation. Bone Marrow Transplant. 17:1996;1051-1056.
37. Ditchburn R.K., McQuillin J., Gardner P.S., Court S.D. Respiratory syncytial virus in hospital cross-infection. Br. Med. J. 3:1971;671-673.
38. Dowell S.F., Anderson L.J., Gary H.E. Jr., Erdman D.D., Plouffe F., File T.M. Jr., Marston B.J., Breiman R.F. Respiratory syncytial virus is an important cause of community acquired lower respiratory infection among hospitalized adults. J. Infect. Dis. 174:1996;456-462.
39. Dubovi E.J., Geratz J.D., Tidwell R.R. Inhibition of respiratory syncytial virus by bis (5-amidino-2-benzimidazoly) methane. Virology. 103:1980;502-509.
40. Dubovi E.J., Geratz J.D., Shaver S.R., Tidwell R.R. Inhibition of respiratory syncytial virus-host cell interactions by mono- and diamidines. Antimicrob. Agents Chemother. 19:1981;649-656.
41. Englund J.A., Glezen W.P. Maternal immunization for the prevention of infection in early infancy. Semin. Pediatr. Infect. Dis. 2:1991;225-231.
42. Englund J.A., Sullivan C.J., Jordan M.C., Dehner L.P., Vercellotti G.M., Balfour H.J. Jr. Respiratory syncytial virus infection in immunocompromised adults. Ann. Intern. Med. 109:1988;203-208.
43. Englund J.A., Piedra P.A., Jefferson L.S., Wilson S.Z., Taber L.H., Gilbert B.E. High-dose, short-duration ribavirin aerosol therapy in children with suspected respiratory syncytial virus infection. J. Pediatr. 117:1990;313-320.
44. Englund J.A., Anderson L.J., Rhame F.S. Nosocomial transmission of respiratory syncytial virus in immunocompromised adults. J. Clin. Microbiol. 29:1991;115-119.
45. Englund J.A., Piedra P.A., Ahn Y.M., Gilbert B.E., Hiatt P. High-dose, short-duration ribavirin aerosol therapy compared with standard ribavirin therapy in children with suspected respiratory syncytial virus infection. J. Pediatr. 125:1994;635-641.
46. Englund J.A., Piedra P.A., Gilbert B.E. Cost of ribavirin therapy for respiratory syncytial virus infection - reply. J. Pediatr. 126:1995;847-847.
47. Englund J.A., Piedra P.A., Whimbey E. Prevention and treatment of respiratory syncytial virus and parainfluenza viruses in immunocompromised patients. Am. J. Med. 102:1997;61-70.
48. Eriksson B., Helgstrand E., Johansson N.G., Larsson A., Misiorny A., Noren J.O., Philipson L., Stenberg K., Stening G., Stridh S., Oberg B. Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob. Agents Chemother. 11:1977;946-951.
49. Falsey A.R., Cunningham C.K., Barker W.H., Kouides R.W., Yuen J.B., Menegus M., Weiner L.B., Bonville C.A., Betts R.F. Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J. Infect. Dis. 172:1995;389-394.
50. Falsey A.R., Walsh E.E. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly. Vaccine. 15:1997;1130-1132.
51. Finger R., Anderson L.J., Dicker R.C., Harrison B., Doan R., Downing A., Corey L. Epidemic respiratory syncytial virus infection in institutionalized young adults. J. Infect. Dis. 155:1987;1335-1339.
52. Fleming D.M., Cross K.W. Respiratory syncytial virus or influenza. Lancet. 342:1993;1507-1510.
53. Fulginiti V.A., Eller J.J., Sieber O.F., Joyner J.W., Minamitani M., Meiklejohn G. Respiratory virus immunization I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am. J. Epidemiol. 89:1969;435-438.
54. Gabrielsen B., Phelan M.J., Barthel-Rosa L., See C., Huggins J.W., Kefauver D.F., Monath T.P., Ussery M.A., Chmurny G.N., Schubert E.M., Upadhya K., Kwong C., Carter D.A., Secrist III J.A., Kirsi J.J., Shannon W.M., Sidwell R.W., Kini G.D., Robins R.K. Synthesis and antiviral evaluation of N-carboxamidine-substituted analogues of 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine hydrochloride. J. Med. Chem. 35:1992;3231-3238.
55. Gardner P.S. Respiratory syncytial virus infections. Postgrad. Med. J. 49:1973;788-791.
56. Gardner, P.S., McQuillan, J., 1974. Rapid Virus Diagnosis: Application of Immunofluorescence. Butterworth, London.
57. Garvie D.G., Gray J. Outbreak of respiratory syncytial virus infection in the elderly. Br. Med. J. 281:1980;1253-1254.
58. Gilbert B.E., Knight V. Biochemistry and clinical applications of ribavirin. Antimicrob. Agents Chemother. 30:1986;201-205.
59. Gilbert B.E., Wyde P.R., Ambrose M.W., Wilson S.Z., Knight V. Further studies with short duration ribavirin aerosol for the treatment of influenza virus in mice and respiratory syncytial virus in cotton rats. Antiviral Res. 17:1992;33-42.
60. Gilbert B.E., Wyde P.R., Wilson S.Z., Meyerson L.R. SP-303 small particle aerosol treatment of influenza A virus infection in mice and respiratory syncytial virus infection in cotton rats. Antiviral Res. 21:1993;37-45.
61. Glezen W.P., Denny F.W. Epidemiology of acute lower respiratory disease in children. New Engl. J. Med. 11:1973;239-243.
62. Glezen W.P., Paredes A., Allison J.E., Taber L.H. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group and maternal antibody level. Pediatrics. 98:1981;708-715.
63. Goswami B.B., Borek E., Sharma O.K. The broad spectrum antiviral agent ribavirin inhibits capping of mRNA. Biochem. Biophys. Res. Commun. 89:1979;830-836.
64. Griffin F.J., Greenough A., Yuksel B. Antiviral therapy in neonatal chronic lung disease. Early Hum. Dev. 42:1995;97-109.
65. Groothuis J.R. The role of RSV neutralizing antibodies in the treatment and prevention of respiratory syncytial virus infection in high-risk children. Antiviral Res. 23:1994;1-10.
66. Groothuis J.R., Gutierrez K.M., Lauer B.A. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics. 82:1988;192-203.
67. Groothuis J.R., Salbenblatt C.K., Lauer B.A. Severe respiratory syncytial virus infection in older children. Am. J. Dis. Child. 144:1990;346-348.
68. Groothuis J.R., Woodin K.A., Katz R., Robertson A.D., McBride J.T., Hall C.B., McWilliams B.C., Lauer B.A. Early ribavirin treatment of respiratory syncytial viral infection in high-risk children. J. Pediatr. 117:1990;792-798.
69. RSVIG Study Group, Groothuis J.R., Levin M.J., Rodriguez W., Hall C.B., Long C.E., Kim H.W., Lauer B.A., Hemming V.G. Use of intravenous gamma globulin to passively immunize high-risk children againstintravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. Antimicrob. Agents Chemother. 35:1991;1469-1473.
70. The Respiratory Syncytial Virus Immune Globulin Study Group, Groothuis J.R., Simoes E.A., Levin M.J., Hall C.B., Long C.E., Rodriguez W.J., Arrobio J., Meissner H.C., Fulton D.R., Welliver R.C., Tristram D.A., Siber G.R., Prince G.A., Van Raden M., Hemming V.G. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. New Engl. J. Med. 329:1993;1524-1530.
71. Groothuis J.R., Simoes E.A., Hemming V.G. Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Respiratory Syncytial Virus Immune Globulin Study Group. Pediatrics. 95:1995;463-467.
72. Groothuis J.R., King S.J., Hogerman D.A., Paradiso P.R., Simoes E.A. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary displasia. J. Infect. Dis. 177:1998;467-469.
73. Gruber W.C., Wilson S.Z., Throop B.J., Wyde P.R. Combined immunoprophylaxis and ribavirin therapy of respiratory syncytial virus (RSV) infection in the cotton rat. Pediatr. Res. 21:1987;270-274.
74. Hall C.B., Douglas R.G. Modes of transmission of respiratory syncytial virus. J. Pediatr. 99:1981;100-103.
75. Hall W.J., Hall C.B., Speers D.M. Respiratory syncytial virus infection in adults. Clinical, virologic, and serial pulmonary function studies. Ann. Intern. Med. 88:1978;203-205.
76. Hall C.B., Douglas R.G. Jr., Geiman J.M. Possible transmission by fomites of respiratory syncytial virus. J. Infect. Dis. 141:1980;98-102.
77. Hall C.B., McBride J.T., Walsh E.E., Bell D.M., Gala C.L., Hildreth S., Ten Eyck L.G., Hall W.J. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. New Engl. J. Med. 308:1983;1443-1447.
78. Hall C.B., Walsh E.E., Hruska J.F., Betts R.F., Hall W.J. Ribavirin treatment of experimental respiratory syncytial viral infection. A controlled double-blind study in young adults. J. Am. Med. Assoc. 249:1983;2666-2670.
79. Hall C.B., McBride J.T., Gala C.L., Hildreth S.W., Schnabel K.C. Ribavirin treatment of respiratory syncytial virus infection in infants with underlying cardiopulmonary disease. J. Am. Med. Assoc. 254:1985;3047-3051.
80. Hall C.B., Powell K.R., MacDonald N.E., Gala C.L., Menegus M.E., Suffin S.C., Cohen H.J. Respiratory syncytial viral infection in children with compromised immune function. New Engl. J. Med. 315:1986;77-81.
81. Hall C.B., Walsh E.E., Schnabel K.C., Long C.E., McConnochie K.M., Hildreth S.W., Anderson L.J. Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children. J. Infect. Dis. 162:1990;1283-1290.
82. Harrington R.D., Hooton T.M., Hackman R.C., Storch G.A., Osborne B., Gleaves C.A., Benson A., Meyers J.D. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J. Infect. Dis. 165:1992;987-993.
83. Hart R.J.C. An outbreak of respiratory syncytial virus infection in an old people's home. J. Infect. 8:1984;259-261.
84. Hasui M., Matsude M., Okutani K., Shigeta S. In vitro antiviral activities of sulfated polysacharides from a marine microalga (Cochlodinium polykritoides) against human immunodeficiency virus and other enveloped viruses. Int. J. Biol. Macromol. 17:1995;293-297.
85. Hayden F.G. Combination antiviral therapy for respiratory virus infections. Antiviral Res. 29:1996;45-48.
86. Hemming V.G., Rodriguez W., Kim H.W., Brandt C.D., Parrott R.H., Burch B., Prince G.A., Baron P.A., Fink R.J., Reaman G. Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children. Antimicrob. Agents Chemother. 31:1987;1882-1886.
87. Hendry R.M., Tulis A.L., Godfrey E., Anderson L.J., Fernie B.F., McIntosh K. Concurrent circulation of antigenically distinct strains of respiratory syncytial virus during community outbreaks. J. Infect. Dis. 153:1986;291-297.
88. Hendry R.M., Burns J.C., Walsh E.E., Graham B.S., Wright P.F., Hemming V.G., Rodriguez W.J., Kim H.W., Prince G.A., McIntosh K., Chanock R.M., Murphy B.R. Strain-specific serum antibody responses in infants undergoing primary infection with respiratory syncytial virus. J. Infect. Dis. 157:1988;640-647.
89. Hendry R.M., Pierik L.T., McIntosh K. Prevalence of respiratory syncytial virus subgroups over six consecutive outbreaks: 1981-1987. J. Infect. Dis. 160:1989;185-190.
90. Hertz M.I., Englund J.A., Snover D., Bitterman P.B., McGlave P.B. Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: a clinical approach and review of the literature. Medicine. 68:1989;269-281.
91. Homa F.L., Brideau R.J., Lehman D.J., Thomsen D.R., Olmsted R.A., Wathen M.W. Development of a novel subunit vaccine that protects cotton rats against both human respiratory syncytial virus and human parainfluenza virus type-3. Gen. Virol. 74:1993;1995-1999.
92. Hosoya M., Balzarini J., Shigeta S., De Clercq E. Differential inhibitory effects of sulfated polysaccharides and polymers on the replication of various myxoviruses and retroviruses, depending on the composition of the target amino acid sequences of the viral envelope glycoproteins. Antimicrob. Agents Chemother. 35:1991;2515-2520.
93. Hruska J.F., Morrow P.E., Suffin S.C., Douglas R.G. In vivo inhibition of respiratory syncytial virus by ribavirin. Antimicrob. Agents Chemother. 21:1982;125-130.
94. Huang R.C., Panin M., Romito R.R., Huang Y.T. Inhibition of replication of human respiratory syncytial virus by 6-diazo-5-oxo-L-norleucine. Antiviral Res. 25:1994;269-279.
95. Ikeda S., Neyts J., Verma S., Wickramasinghe A., Mohan P., De Clercq E. In vitro and in vivo inhibition of ortho- and paramyxovirus infections by a new class of sulfonic acid polymers interacting with virus-cell binding and/or fusion. Antimicrob. Agents Chemother. 38:1994;256-259.
96. Jairath S., Vargas P.B., Hamlin H.A., Field A.K., Kilkuskie R.E. Inhibition of respiratory syncytial virus replication by antisense oligodeoxyribonucleotides. Antiviral Res. 33:1997;201-213.
97. Janai H.K., Stutman H.R., Zaleska M., Rub B.E.M., Marks M.I., Nussbaum E. Ribavirin effect on pulmonary function in young infants with respiratory syncytial virus bronchiolitis. Pediatr. Infect. Dis. J. 12:1993;214-218.
98. Johnson S., Oliver C., Prince G.A., Hemming V.G., Pfarr D.S., Wang S.C., Dormitzer M., O'Grady J., Koenig S., Tamura J.K., Woods R., Bansal G., Couchenour D., Tsao E., Hall W.C., Young J.F. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 176:1997;1215-1224.
99. Johnson K.M., Chanock R.M., Rifkind D., Kravetz H.M., Knight V. Respiratory syncytial virus: IV. Correlation of virus shedding, serological response, and illness in adult volunteers. J. Am. Med. Assoc. 176:1998;663-667.
100. Kawana F., Shigeta S., Hosoya M., Suzuki H., De Clercq E. Inhibitory effects of antiviral compounds on respiratory syncytial virus replication in vitro. Antimicrob. Agents Chemother. 31:1987;1225-1230.
101. Kim H.W., Arroyo J.O. Epidemiology of respiratory syncytial virus in Washington, DC. I. Importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection. Am. J. Epidemiol. 98:1973;216-225.
102. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., Jensen K., Parrot R.H. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89:1969;422-434.
103. Kim H.W., Arrobio J.O., Brandt C.D., Wright P., Hodes D., Chanock R.M., Parrott R.H. Safety and antigenicity of temperature sensitive (ts) mutant respiratory syncytial virus (RSV) in infants and children. Pediatrics. 52:1973;56-63.
104. King J.C. Jr., Burke A.R., Clemens J.D., Nair P., Farley J.J., Vink P.E., Batlas S.R., Rao M., Johnson J.P. Respiratory syncytial virus illness in human immunodeficiency virus-infected and noninfected children. Pediatr. Infect. Dis. J. 12:1993;733-739.
105. Kolocouris N., Foscolos G.B., Kolocouris A., Marakos P., Pouli N., Fytas G., Ikeda S., De Clercq E. Synthesis and antiviral activity evaluation of some aminoadamantane derivatives. J. Med. Chem. 37:1994;2896-2902.
106. Krowka M.J., Rosenow E.C., Hoagland H.C. Pulmonary complications of bone marrow transplantation. Chest. 87:1985;237-246.
107. Kuntz I.D. Structure-based strategies for drug design and discovery. Science. 25:1992;1078-1082.
108. La Via W.V., Marks M.I., Stutman H.R. Respiratory syncytial virus puzzle: clinical features, pathophysiology, treatment and prevention. J. Pediatr. 121:1992;503-510.
109. Law B.J., Wang E.E., Stephens D. Ribavirin does not reduce hospital stay (LOS) in patients with respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI). Pediatr. Res. 37:1995;110A.
110. Lewinsohn D.M., Bowden R.A., Mattson D., Crawford S.W. Phase 1 study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation. Antimicrob. Agents Chemother. 40:1996;2555-2557.
111. Luo M., Air G.M., Brouillet W.J. Design of aromatic inhibitors of influenza virus neuraminidase. J. Infect. Dis. 176:1997;S62-65.
112. Martin A.J., Gardner P.S., McQuillin J. Epidemiology of respiratory viral infection among pediatric inpatients over a six year period in northeast England. Lancet. 2:1978;1035-1038.
113. Martin M.A., Bock M.J., Pfaller M.A., Wenzel R.P. Respiratory syncytial virus infections in adult bone marrow transplant recipients (letter). Lancet. 1:1988;1396-1397.
114. Mastronarde J.G., Monick M.M., Gross T.J., Hunninghake G.W. Amiloride inhibits cytokine production in epithelium infected with respiratory syncytial virus. Am. J. Physiol. 271:1996;L201-L207.
115. McColl M.D., Corser R.B., Bremner J., Chopra R. Respiratory syncytial virus infection in adult BMT recipients: effective therapy with short duration nebulised ribavirin. Bone Marrow Transplant. 21:1998;423-425.
116. McIntosh K. Respiratory syncytial virus infections in infants and children: diagnosis and treatment. Pediatr. Res. 9:1987;191-196.
117. McIntosh, K., Chanock, R.M., 1990. Respiratory syncytial virus. In: Fields, B., Knipe, D.M., Chanock, R.M., Hirsch, M.S., Melnick, J.L., Monath, T.P., Roizman, B. (Eds.), Fields Virology, 2nd ed. Raven Press, New York, pp. 1045-1074.
118. McIntosh K., Ellis E.F., Hoffman L.S. The association of viral and bacterial respiratory infections with exacerbations of wheezing in young asthmatic children. J. Pediatr. 82:1973;578-590.
119. McIntosh K., Kurachek S.C., Cairns L.M., Burns J.C., Goodspeed B. Treatment of respiratory syncytial viral infection in an immunodeficient infant with ribavirin aerosol. Am. J. Dis. Child. 138:1984;305-308.
120. Medical Research Council Subcommittee on Respiratory Syncytial Virus Vaccines Respiratory syncytial virus infection: admissions to hospital in industrial, urban, and rural areas. Br. Med. J. 2:1978;796-798.
121. Medimmune, Inc., 1997. Medimmune announces MEDI-493 publication. Data presented in the Journal of Infectious Diseases. http://www.medimmune.com [accessed 02/02/98] 1-2.
122. Meert K.L., Sarnaik A.P., Gelmini M.J., Lieh-Lai M.W. Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory disease: a prospective, double-blind randomized trial. Crit. Care Med. 22:1994;566-572.
123. Meissner H.C., Fulton D.R., Groothuis J.R., Geggel R.L., Marx G.R., Hemming V.G., Hougen T., Snydman D.R. Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin. Antimicrob. Agents Chemother. 37:1993;1655-1658.
124. Mlinaric-Galinovic G., Chonmaitree T., Cane P.A., Pringle C.R., Ogra P.L. Antigenic diversity of respiratory syncytial virus subgroup B strains circulating during a community outbreak of infection. J. Med. Virol. 42:1994;380-384.
125. Moler F.W., Steinhart C.M., Ohmit S.E., Stidham G.L. Effectiveness of ribavirin in otherwise well infants with respiratory syncytial virus-associated respiratory failure. J. Pediatr. 128:1996;422-428.
126. Mufson M.A., Belshe R.B., Orvell C., Norrby E. Subgroup characteristics of respiratory syncytial virus strains recovered from children with two consecutive infections. J. Clin. Microbiol. 25:1987;1535-1539.
127. Mufson M.A., Belshe R.B., Orvell C., Norrby E. Respiratory syncytial virus epidemics: variable dominance of subgroups A and B strains among children. J. Infect. Dis. 157:1988;143-148.
128. Murphy B.R., Collins P.L. Current status of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PiV3) vaccine development: memorandum from a joint WHO/NIAID meeting. Bull. WHO. 75:1997;307-313.
129. Nelson C.T., Englund J.A. New approaches to the use of ribavirin. Semin. Pediatr. Infect. Dis. 7:1996;114-120.
130. Neyts J., Reymen D., Letourneur D., Jozefonicz J., Schols D., Este J., Andrei G., McKenna P., Witvrouw M., Ikeda S., Clements J., De Clercq E. Differential antiviral activity of derivatized dextrans. Biochem. Pharmacol. 50:1995;743-751.
131. Ohmit S.E., Moler F.W., Monto A.S., Khan A.S. Ribavirin utilization and clinical effectiveness in children hospitalized with respiratory syncytial virus infection. J. Clin. Epidemiol. 49:1996;963-967.
132. Oien N.L., Brideau R.J., Walsh E.E., Wathen M.W. Induction of local and systemic immunity against human respiratory syncytial virus using a chimeric FG glycoprotein and cholera toxin B subunit. Vaccine. 12:1994;731-735.
133. Oravax, Inc., 1997. OraVax reports results from phase III trial of HNK20 nosedrop for respiratory syncytial virus in infants. Available from: http://www.oravax.com/news [accessed 02/02/98], 1-2.
134. Ottolini M.G., Hemming V.G. Prevention and treatment recommendations for respiratory syncytial virus infection - background and clinical experience 40 years after discover. Drugs. 54:1997;867-884.
135. Patil S.D., Schneller S.W., Hosoya M., Snoeck R., Andrei G., Balzarini J., De Clercq E. Synthesis and antiviral properties of (±)-5′ noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design. J. Med. Chem. 35:1992;3372-3377.
136. Piedra P.A., Glezen W.P., Kasel J.A., Welliver R.C., Jewel A.M., Rayford Y., Hogerman D.A., Hildreth S.W., Paradiso P.R. Safety and immunogenicity of the PFP vaccine against respiratory syncytial virus (RSV): the Western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection. Vaccine. 13:1995;1095-1101.
137. Piedra P.A., Grace S., Jewell A., Spinelli S., Bunting D., Hogerman D.A., Malinoski F., Hiatt P.W. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr. Infect. Dis. J. 15:1996;23-31.
138. Pirofski L.A., Casadevall A. Use of licensed vaccines for active immunization of the immunocompromised host. Clin. Microbiol. Rev. 11:1998;1-10.
139. Powers D.C., Hanscome P.J., Pietrobon P.J.F. In previously immunized elderly adults inactivated influenza A (H1N1) virus vaccines induce poor antibody responses that are not enhanced by liposome adjuvant. Vaccine. 13:1995;1330-1335.
140. PREVENT Study Group Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics. 99:1997;93-99.
141. Raineri I., Huang T.T., Epstein C.J., Epstein L.B. Antisense manganese superoxide dismutase mRNA inhibits the antiviral action of interferon-gamma and interferon-alpha. J. Interferon Cytokine Res. 16:1996;61-68.
142. Randolph A.G., Wang E.E. Ribavirin for respiratory syncytial virus lower respiratory tract infection - a systematic overview. Arch. Pediatr. Adolescent Med. 150:1996;942-947.
143. Randolph V.B., Kandis M., Stemler-Higgins P., Kennelly M.S., McMullen Y.M., Speelman D.J., Weeks-Levy C. Attenuated temperature-sensitive respiratory syncytial virus mutants generated by cold adaptation. Virus Res. 33:1994;241-259.
144. Reuman P.D., Keely S.P., Schiff G.M. Rapid recovery in mice after combined nasal/oral immunization with killed respiratory syncytial virus. J. Med. Virol. 32:1990;67-72.
145. Richardson L.S., Belshe R.B., London W.T., Sly D.L., Prevar D.A., Camargo E., Chanock R.M. Evaluation of five temperature-sensitive mutants of respiratory syncytial virus in primates: 1. Viral shedding, immunologic response, and associated illness. J. Med. Virol. 3:1978;91-100.
146. Rodriguez W.J., Kim H.W., Brandt C.D., Fink R.J., Getson P.R., Arrobio J., Murphy T.M., McCarthy V., Parrott R.H. Aerosolized ribavirin in the treatment of patients with respiratory syncytial virus disease. Pediatr. Infect. Dis. J. 6:1987;159-163.
147. Rodriguez W.J., Gruber W.C., Groothuis J.R., Simoes E.A., Rosas A.J., Lepow M., Kramer A., Hemming V. Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children. Pediatrics. 100:1997;937-942.
148. Rodriguez W.J., Gruber W.C., Welliver R.C., Groothuis J.R., Simoes E.A., Meissner C., Hemming V., Hall C.B., Lepow M.L., Rosas A.J., Robertsen C., Kramer A.A. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group. Pediatrics. 99:1997;455-461.
149. Sable C.A., Hayden F.G. Orthomyxoviral and paramyxoviral infections in transplant patients. Infect. Dis. Clin. North Am. 9:1995;987-1003.
150. Selway C.N., Terrett N.K. Parallel-compound synthesis: methodology for accelerating drug discovery. Bioorgan. Med. Chem. 4:1996;645-654.
151. Selwyn B.J. The epidemiology of acute respiratory tract infection in young children. Res. Infect. Dis. 12:1990;5870-5888.
152. Shigeta S., Mori S., Baba M., Ito M., Honzumi K., Nakamura K., Oshitani H., Numazaki Y., Matsuda A., Obara T., Shuto S., De Clercq E. Antiviral activities of ribavirin, 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide, and 6′-(R)-6′-C-methylneplanocin A against several ortho- and paramyxoviruses. Antimicrob. Agents Chemother. 36:1992;435-439.
153. Shigeta S., Mori S., Watanabe J., Baba M., Khenkin A.M., Hill C.L., Schinazi R.F. In vitro antimyxovirus and anti-human immunodeficiency virus activities of polyoxometalates. Antiviral Res. 6:1995;114-122.
154. Shuto S., Obara T., Toriya M., Hosoya M., Snoeck R., Andrei G., Balzarini J., De Clercq E. New neplanocin analogues. 1. Synthesis of 6′-modified neplanocin A derivatives as broad-spectrum antiviral agents. J. Med. Chem. 35:1992;324-331.
155. Siber G.R., Lesczynski J., Pena-Cruz V., Ferren-Gardner C., Anderson R., Hemming V.G., Walsh E.E., Burns J., McIntosh K., Gonin R., Anderson L.J. Protective activity of a human respiratory syncytial virus immune globulin prepared from donors screened by microneutralization assay. J. Infect. Dis. 165:1992;456-463.
156. Siddiqi S.M., Chen X., Schneller S.W. Antiviral enantiomeric preference for 5′-noraristeromycin. J. Med. Chem. 37:1994;551-554.
157. Siddiqi S.M., Chen X., Schneller S.W., Ikeda S., Snoeck R., Andrei G., Balzarini J., De Clercq E. An epimer of 5′-noraristeromycin and its antiviral properties. J. Med. Chem. 37:1994;1382-1384.
158. Siddiqi S.M., Chen X., Rao J., Schneller S.W. 3-deaza- and 7-deaza-5′-noraristeromycin and their antiviral properties. J. Med. Chem. 38:1995;1035-1038.
159. Sidwell R.W., Huffman J.H., Khare G.P., Allen L.B., Witkowski J.T., Robins R.K. Broad-spectrum antiviral activity of virazole: 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science. 177:1972;705-706.
160. Simoes E.A.F., Sondheimer H.M., Meissner H.C.et al. Respiratory syncytial virus immunoglobulin as prophylaxis against respiratory syncytial virus in children with congenital heart disease (abstract). Pediatr. Res. 39:1996;113A.
161. Sims D.G., Downham M.A., Webb K.G., Gardner P.S., Weightman D. Hospital cross-infection on children's wards with respiratory syncytial virus and the role of adult carraige. Acta Paediatr. Scand. 64:1975;541-545.
162. Six, H.R., Gilbert, B.E., Wyde, P.R., Wilson, S.Z., Knight, V., 1988. Liposomes as carriers of enviroxime for use in aerosol therapy of rhinovirus infection. In: Lopez-Berestein, G., Fidler, I. (Eds.), Lipsomes in the Therapy of Infectious Diseases and Cancer (UCLA Symposia on Molecular and Cellular Biology), Alan R. Liss, New York.
163. Smith D.W., Frankel L.R., Mathers L.H., Tang A.T.S., Ariagno R.L., Prober M.D. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infections. Pediatr. Pulmonol. 13:1991;143-150.
164. Snell N.J.C. Economic and long-term benefits of ribavirin therapy on respiratory syncytial virus infection. Lung. 168(Suppl):1990;422-429.
165. Solomon L.R., Raftery A.T., Mallick N.P., Johnson R.W.G., Longson M. Respiratory syncytial virus infection following renal transplantation. J. Infect. 3:1981;280-282.
166. Sparrelid E., Ljungman P., Ekelof Andstrom E., Aschan J., Ringden O., Winiarski J., Wahlin B., Andersson J. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infection. Bone Marrow Transplant. 19:1997;905-908.
167. Sung R.Y.T., Yin J., Oppenheimer S.J., Tam J.S., Lau J. Treatment of respiratory syncytial virus infection with recombinant interferon alfa-2a. Arch. Dis. Child. 69:1993;440-442.
168. Taber L.H., Knight V., Gilbert B.E., McClung H.W., Wilson S.Z., Norton H.J., Thurston J.M., Gordon W.H., Atmar R.L., Schauldt W.R. Ribasvirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. Pediatrics. 72:1983;613-618.
169. Tang Y.W., Graham B.S. Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus. J. Clin. Invest. 94:1994;1953-1958.
170. Taylor G., Porter T., Dillon S., Trill J., Ganguly S., Hart T., Davis C., Wyde P., Tempest P., Harris W. Anti-respiratory syncytial virus monoclonal antibodies show promise in the treatment and prophylaxis of viral disease. Biochem. Soc. Trans. 23:1995;1063-1067.
171. Tempest P.R., Bremer P., Lampbert M., Taylor G., Furze J.M., Car F.J., Harris W.J. Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo. Biotechnol. 9:1991;266-271.
172. Torrence P.F., Xiao W., Li G., Cramer H., Player M.R., Silverman R.H. Recruiting the 2-5A system for antisense therapeutics. Antisense Nucleic Acid Drug Dev. 7:1997;203-206.
173. Tristram D.A., Welliver R.C., Hogerman D.A., Hildreth S.W., Paradiso P. Second-year surveillance of recipients of a respiratory syncytial virus (RSV) F protein subunit vaccine, PFP-1 - evaluation of antibody persistence and possible disease enhancement. Vaccine. 12:1994;551-556.
174. Vikerfors T., Grandien M., Olcen P. Respiratory syncytial virus infection in adults. Am. Rev. Respir. Dis. 136:1987;561-564.
175. Wald E.R., Dashefsky B. Red Book Committee recommendation questioned. Pediatrics. 94:1994;672-673.
176. Walsh E.E., Schlesinger J.J., Brandriss M.W. Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies. Infect. Immun. 43:1984;756-758.
177. Wathen M.W., Brideau R.J., Thomsen D.R. Immunization of cotton rats with the human respiratory syncytial virus F glycoprotein produced using a baculovirus vector. J. Infect. Dis. 159:1989;255-264.
178. Wathen M.W., Kakuk T.J., Brideau R.J., Hausknecht E.C., Cole S.L., Zaya R.M. Vaccination of cotton rats with a chimeric FG glycoprotein of human respiratory syncytial virus induces minimal pulmonary pathology on challenge. J. Infect. Dis. 163:1991;477-482.
179. Watt P.J., Robinsion B.S., Pringle C.R., Tyrrell D.A.J. Determinants of susceptibility to challenge and the antibody response of adult volunteers given experimental respiratory syncytial virus vaccines. Vaccine. 8:1990;231.
180. Weltzin R., Hsu S.A., Mittler E.S., Georgakopoulos K., Monath T.P. Intranasal monoclonal immunoglobulin A against respiratory syncytial virus protects against upper and lower respiratory tract infections in mice. Antimicrob. Agents Chemother. 38:1994;2785-2791.
181. Weltzin R., Traina-Dorge V., Soike K., Zhang J.Y., Mack P., Soman G., Drabik G., Monath T.P. Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection. J. Infect. Dis. 174:1996;256-261.
182. Wheeler J.G., Wofford J., Turner R.B. Historical cohort evaluation of ribavirin efficacy in respiratory syncytial virus infection. Pediatr. Infect. Dis. J. 12:1993;209-213.
183. Whimbey E., Champlin R.E., Englund J.A., Mirza N.Q., Piedra P.A., Goodrich J.M., Przepiorka D., Luna M.A., Morice R.C., Neumann J.L., Elting L.S., Bodey G.P. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant. 16:1995;393-399.
184. Whimbey E., Couch R.B., Englund J.A., Andreeff M., Goodrich J.M., Raad I.I., Lewis V., Mirza N., Luna M.A., Baxter B., Tarrand J.J., Bodey G.P. Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia. Clin. Infect. Dis. 21:1995;376-379.
185. Whimbey E., Champlin R.E., Couch R.B., Englund J.A., Goddrich J.M., Raad I., Przepiorka D., Lewis V.A., Mirza N., Yousu H., Tarrand J.J., Bodey G.P. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin. Infect. Dis. 22:1996;778-782.
186. Whittle P.J., Blundell T.L. Protein structure-based drug design. Annu. Rev. Biophys. Biomol. Struct. 23:1994;349-375.
187. Witvrouw M., Desmyter J., De Clercq E. Antiviral portrait series: 4. Polysulfates as inhibitors of HIV and other enveloped viruses. Antiviral Chem. Chemother. 5:1994;345-359.
188. Wray S.K., Gilbert B.E., Noall M.W., Knight V. Mode of action of ribavirin: effect of nucleotide pool alterations on influenza virus ribonucleoprotein synthesis. Antiviral Res. 5:1985;29-37.
189. Wray S.K., Gilbert B.E., Knight V. Effect of ribavirin triphosphate on primer generation and elongation during influenza virus transcription in vitro. Antiviral Res. 5:1985;39-48.
190. Wright P.F., Shinozaki T., Fleet W., Sell S.H., Thompson J., Karzon D.T. Evaluation of a live, attenuated respiratory syncytial virus vaccine in infants. J. Pediatr. 88:1976;931-936.
191. Wright P.F., Belshe R.B., Kim H.W., Van Voris L.P., Chanock R.M. Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children. Infect. Immun. 37:1982;397-400.
192. Wyde P.R., Wilson S.Z., Petrella R., Gilbert B.E. Efficacy of high dose-short duration ribavirin aerosol in the treatment of respiratory syncytial virus infected cotton rats and influenza B virus infected mice. Antiviral Res. 7:1987;211-220.
193. Wyde P.R., Gilbert B.E., Ambrose M.W. Comparison of the anti-respiratory syncytial virus activity and toxicity of papaverine hydrochloride and pyrazofurin in vitro and in vivo. Antiviral Res. 11:1989;15-26.
194. Wyde P.R., Ambrose M.W., Meyer H.L., Zolinski C.L., Gilbert B.E. Evaluation of the toxicity and antiviral activity of carbocyclic 3-deazaadenosine against respiratory syncytial and parainfluenza type 3 viruses in tissue culture and in cotton rats. Antiviral Res. 14:1990;215-225.
195. Wyde P.R., Ambrose M.W., Meyerson L.R., Gilbert B.E. The antiviral activity of SP-303, a natural polyphenolic polymer, against respiratory syncytial and parainfluenza type 3 viruses in cotton rats. Antiviral Res. 20:1993;145-154.
196. Wyde P.R., Meyerson L.R., Gilbert B.E. An in vitro evaluation of the antiviral activity of SP-303, an euphorbiaceae shrub extract, against a panel of respiratory virus. Drug Dev. Res. 28:1993;467-472.
197. Wyde P.R., Moore D.K., Hepburn T., Silverman C.L., Porter T.G., Gross M., Taylor G., Demuth S.G., Dillon S.B. Evaluation of the protective efficacy of reshaped human monoclonal antibody RSHZ19 against respiratory syncytial virus in cotton rats. Pediatr. Res. 38:1995;543-550.
198. Wyde P.R., Moore D.K., Pimentel D.M., Blough H.A. Evaluation of the antiviral activity of N-(phosphonoacetyl)-L-aspartate against paramyxoviruses in tissue culture and against respiratory syncytial virus in cotton rats. Antiviral Res. 27:1995;59-69.
199. Wyde P.R., Moore D.K., Pimentel D.M., Gilbert B.E., Nimrod R., Panet A. Recombinant superoxide dismutase (SOD) administered by aerosol inhibits respiratory syncytial virus infection in cotton rats. Antiviral Res. 31:1996;173-184.
200. Wyde, P.R., Moore-Poveda, D.K., O'Hara, B., Ding, W.-D., Mitsner, B., Gilbert, B.E., 1998. CL387626 exhibits marked and unusual antiviral activity against respiratory syncytial virus in tissue culture in cotton rats. Antiviral Res. 38, 31-42.